Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138331 | 0.98 | HSD11B1 (0.47) | HSD11B1NR1I2ADORA3GRM2CCNE1 | |
| SCHEMBL21138816 | 0.97 | HSD11B1 (0.49) | HSD11B1NR1I2ADORA3GRM2CCNE1 | |
| SCHEMBL21138911 | 0.88 | HSD11B1 (0.37) | HSD11B1NR1I2ADORA3 | |
| SCHEMBL30396230 | 0.87 | HSD11B1 (0.37) | HSD11B1NR1I2ADORA3TNK2CCNE1 | |
| SCHEMBL25525166 | 0.87 | HSD11B1 (0.37) | HSD11B1NR1I2ADORA3TNK2CCNE1 | |
| SCHEMBL19917049 | 0.87 | HSD11B1 (0.37) | HSD11B1NR1I2ADORA3CCNE1CDK2 | |
| SCHEMBL21057446 | 0.87 | HSD11B1 (0.37) | HSD11B1NR1I2ADORA3CCNE1CDK2 | |
| SCHEMBL21138569 | 0.86 | HSD11B1 (0.37) | HSD11B1NR1I2ADORA3 | |
| SCHEMBL21138372 | 0.85 | HSD11B1 (0.50) | HSD11B1NR1I2ADORA3 | |
| SCHEMBL21138810 | 0.83 | ADORA3 (0.38) | HSD11B1NR1I2ADORA3CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | HSD11B1 478/4885NR1I2 2630/4885ADORA3 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.